A decision-support model for evaluating changes in biopharmaceutical manufacturing processes

Bioprocess and Biosystems Engineering

Volumn 30, Issue 1, 2007, Pages 1-11

  Chhatre, S ^a   Francis, R ^b   O'Donovan, K ^b   Titchener Hooker, N J ^a   Newcombe, A R ^b   Keshavarz Moore, E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

Bioprocess; Integrated modelling; Polyclonal antibody; Process change; Simulation

Indexed keywords

BIOPROCESS; INTEGRATED MODELING; POLYCLONAL ANTIBODY; PROCESS CHANGE;

ANTIBODIES; COMPUTER SIMULATION; COSTS; DRUG PRODUCTS; MATHEMATICAL MODELS; PRODUCTION CONTROL;

DECISION THEORY;

CROFAB; IMMUNOGLOBULIN G; PAPAIN; POLYCLONAL ANTIBODY; SNAKE VENOM; SNAKE VENOM ANTISERUM; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AFFINITY LABELING; ARTICLE; BATCH PROCESS; BIOPROCESS; CENTRIFUGATION; COST; DECISION MAKING; DOWNSTREAM PROCESSING; FOOD AND DRUG ADMINISTRATION; ION EXCHANGE; PRECIPITATION; PRIORITY JOURNAL; PROCESS DESIGN; PROTEIN DEGRADATION; SIMULATION; SNAKE; TIME;

BIOPHARMACEUTICS; COMPUTER SIMULATION; DRUG INDUSTRY; IMMUNOGLOBULIN G; REPRODUCIBILITY OF RESULTS;

OVIS;

EID: 33845901257     PISSN: 16157591     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00449-006-0086-8     Document Type: Article

References (24)

1. Titchener-Hooker NJ, Zhou Y, Hoare M, Dunnill P (2001) Biopharmaceutical process development: Part II. Methods of reducing development time. Biopharm Eur 13:68-74
2. Karri S, Davies E, Titchener-Hooker N, Washbrook J (2001) Biopharmaceutical process development: Part III. A framework to assist decision making. Biopharm Eur 13:76-82
3. Farid SS, Washbrook J, Titchener-Hooker NJ (2005) Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol Prog 21:486-497
4. Lim AC, Zhou Y, Washbrook J, Sinclair A, Fish B, Francis R, Titchener-Hooker NJ, Farid SS (2005) Application of a decision-support tool to assess pooling strategies in perfusion culture processes under uncertainty. Biotechnol Prog 21:1231-1242
5. Zhou YH, Titchener-Hooker NJ (1999) Simulation and optimisation of integrated bioprocesses: a case study. J Chem Technol Biotechnol 74:289-292
6. Zhou YH, Titchener-Hooker NJ (1999) Visualising integrated bioprocess designs through, "windows of operation." Biotechnol Bioeng 65:550-557
7. Groep ME, Gregory ME, Kershenbaum LS, Bogle IDL (2000) Performance modelling and simulation of biochemical process sequences with interacting unit operations. Biotechnol Bioeng 67:300-311
8. Li R, Townsend CA (2006) Rational strain improvement for enhanced clavulanic acid production by genetic engineering of the glycolytic pathway in Streptomyces clavuligerus. Metab Eng 8:240-252
9. Lowe CR, Lowe AR, Gupta G (2001) New developments in affinity chromatography with potential application in the production of biopharmaceuticals. J Biochem Biophys Methods 49:561-574
10. Chase HA (1998) The use of affinity adsorbents in expanded bed adsorption. J Mol Recognit 11:217-221
11. González Y, Ibarra N, Gómez H, González M, Dorta L, Padilla S, Valdés R (2003) Expanded bed adsorption processing of mammalian cell culture fluid: comparison with packed bed affinity chromatography. J Chromatogr B 784:183-187
12. Lim AC, Zhou Y, Washbrook J, Titchener-Hooker NJ, Farid S (2004) A decisional-support tool to model the impact of regulatory compliance activities in the biomanufacturing industry. Comput Chem Eng 28:727-735
13. Mustafa MA, Washbrook J, Lim AC, Zhou Y, Titchener-Hooker NJ, Morton P, Berezenko S, Farid SS (2004) A software tool to assist business-process decision-making in the biopharmaceutical industry. Biotechnol Prog 20:1096-1102 [Correction: Biotechnol Prog 21:320 (2005)]
14. Harrison RG, Todd PW, Rudge SR, Petrides DP (2003) Bioprocess design. In: Bioseparations science and engineering. Oxford University Press, New York, pp 319-372
15. Novais JL, Titchener-Hooker NJ, Hoare M (2001) Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. Biotechnol Bioeng 75:143-153
16. Farid SS, Washbrook J, Titchener-Hooker NJ (2005) Combining multiple quantitative and qualitative goals when assessing biomanufacturing strategies under uncertainty. Biotechnol Prog 21:1183-1191
17. AB antivenom. Ann Emerg Med 37:196-201
18. Neal G, Christie J, Keshavarz-Moore E, Ayazi Shamlou P (2003) Ultra scale-down approach for the prediction of full-scale recovery of ovine polyclonal immunoglobulins used in the manufacture of snake venom-specific Fab fragment. Biotechnol Bioeng 81:149-157
19. Neal G, Francis R, Ayazi Shamlou P, Keshavarz-Moore E (2004) Separation of immunoglobulin G precipitate from contaminating proteins using microfiltration. Biotechnol Appl Biochem 39:241-248
20. Newcombe AR, Cresswell C, Davies S, Pearce F, O'Donovan K, Francis R (2006) Evaluation of a biosensor assay to quantify polyclonal IgG in ovine serum used for the production of biotherapeutic antibody fragments. Proc Biochem 41:842-847
21. Newcombe AR, Cresswell C, Davies S, Watson K, Harris G, O'Donovan K, Francis R (2005) Optimised affinity purification of polyclonal antibodies from hyper immunised ovine serum using a synthetic Protein A adsorbent, MAbsorbent® A2P. J Chromatogr B 814:209-215
22. Tejeda-Mansir A, Espinoza R, Montesinos RM, Guzman R (1997) Modelling regeneration effects on protein A affinity chromatography. Bioproc Eng 17:39-44
23. Huse K, Böhme H-J, Scholz GH (2002) Review article: Purification of antibodies by affinity chromatography. J Biochem Biophys Methods 51:217-231
24. Thillaivinayagalingam P, O'Donovan K, Newcombe AR, Keshavarz-Moore E (2006) Characterisation of an industrial affinity process used in the manufacturing of digoxin-specific polyclonal Fab fragments. J Chromatogr B (in press)